Inovio Pharmaceuticals, Inc. (INO) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Inovio (INO) Q1 2026: Cash Runway Extended to Q1 2027 as INO3107 Nears FDA Milestone
May 14, 2026
-
Inovio (INO) Q4 2025: Operating Expenses Drop 23% as INO3107 FDA Review Drives Resource Focus
March 13, 2026
-
Inovio (INO) Q3 2025: Operating Expenses Cut 22% as 3107 BLA Submission Drives Strategic Focus
November 11, 2025
-
Inovio (INO) Q2 2025: Operating Expenses Drop 31% as 3107 Nears BLA Submission
August 13, 2025